ANCOTIL 10 mg/ml infuusioneste Suomi - suomi - Fimea (Suomen lääkevirasto)

ancotil 10 mg/ml infuusioneste

f.hoffmann-la roche ltd - flucytosinum - infuusioneste - 10 mg/ml - flusytosiini

ANCOTIL 500 mg tabletti Suomi - suomi - Fimea (Suomen lääkevirasto)

ancotil 500 mg tabletti

f.hoffmann-la roche ltd - flucytosinum - tabletti - 500 mg - flusytosiini

METOSINAT 23.75 mg depottabletti Suomi - suomi - Fimea (Suomen lääkevirasto)

metosinat 23.75 mg depottabletti

hexal ag - metoprololi succinas - depottabletti - 23.75 mg - metoprololi

METOSINAT 47.5 mg depottabletti Suomi - suomi - Fimea (Suomen lääkevirasto)

metosinat 47.5 mg depottabletti

hexal ag - metoprololi succinas - depottabletti - 47.5 mg - metoprololi

METOSINAT 95 mg depottabletti Suomi - suomi - Fimea (Suomen lääkevirasto)

metosinat 95 mg depottabletti

hexal ag - metoprololi succinas - depottabletti - 95 mg - metoprololi

METOSINAT 142.5 mg depottabletti Suomi - suomi - Fimea (Suomen lääkevirasto)

metosinat 142.5 mg depottabletti

hexal ag - metoprololi succinas - depottabletti - 142.5 mg - metoprololi

METOSINAT 190 mg depottabletti Suomi - suomi - Fimea (Suomen lääkevirasto)

metosinat 190 mg depottabletti

hexal ag - metoprololi succinas - depottabletti - 190 mg - metoprololi

Slentrol Euroopan unioni - suomi - EMA (European Medicines Agency)

slentrol

zoetis belgium sa - dirlotapidi - antiobesity preparations, excl. ruokavalion tuotteita - koirat - apuna ylipainoisuuden ja lihavuuden hallinnassa aikuisille koirille. voidaan käyttää osana yleistä painonhallintaohjelmaa, johon sisältyy myös asianmukaisia ​​ruokavalion muutoksia ja harjoittelua.

Zolsketil pegylated liposomal Euroopan unioni - suomi - EMA (European Medicines Agency)

zolsketil pegylated liposomal

accord healthcare s.l.u. - doxorubicin hydrochloride, liposomal - ovarian neoplasms; sarcoma, kaposi; multiple myeloma - doxorubicin - zolsketil pegylated liposomal is a medicine used to treat the following types of cancer in adults:• breast cancer that has spread to other parts of the body in patients at risk of heart problems. zolsketil pegylated liposomal is used on its own for this disease;• advanced ovarian cancer in women whose previous treatment including a platinum-based cancer medicine has stopped working;• multiple myeloma (a cancer of the white blood cells in the bone marrow), in patients with progressive disease who have received at least one other treatment in the past and have already had, or are unsuitable for, a bone marrow transplantation. zolsketil pegylated liposomal is used in combination with bortezomib (another cancer medicine);• kaposi’s sarcoma in patients with aids who have a very damaged immune system. kaposi’s sarcoma is a cancer that causes abnormal tissue to grow under the skin, on moist body surfaces or on internal organs. zolsketil pegylated liposomal contains the active substance doxorubicin and is a ‘hybrid medicine’. this means that it is similar to a ‘reference medicine’ containing the same active substance called adriamycin. however, in zolsketil pegylated liposomal the active substance is enclosed in tiny fatty spheres called liposomes, whereas this is not the case for adriamycin.

Bricanyl Turbuhaler 0.5 mg/annos inhalaatiojauhe Suomi - suomi - Fimea (Suomen lääkevirasto)

bricanyl turbuhaler 0.5 mg/annos inhalaatiojauhe

astrazeneca oy - terbutaline sulfate - inhalaatiojauhe - 0.5 mg/annos - terbutaliini